fda compounding glp-1 enforcement news The is proposing the removal of three drugs from the 503B bulks list of active ingredients that outsourcing facilities can use to make compounded medicines, the agency announced on Thursday FDA is moving to restrict

Ozempic lawsuits allege Novo Nordisk failed to adequately warn patients and healthcare providers about serious gastrointestinal risks including gastroparesis, pancreatitis, bowel obstruction, and vision loss (NAION)

Personal testing and a doctor inform dose and schedule

C., Amiel, S

Lilly is racing to file orforglipron for type 2 diabetes in 2026 while advancing retatrutide toward what could be the most efficacious obesity therapy yet studied

This is because they mimic a natural hormone that regulates appetite and glucose

This process produces compounds called short-chain fatty acids (SCFAs) , which have been shown to stimulate GLP-1 secretion from specialized cells in the gut